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Abstract
Fear of cancer recurrence is broadly defined as the fear or worry that cancer could return or progress in the same 
place or another part of the body. It is frequently reported as an unmet need by cancer survivors, and does not 
appear to diminish with time since diagnosis and treatment completion. Fear of cancer recurrence is almost 
universal among cancer survivors, and those experiencing high levels of fear of cancer recurrence experience 
difficulties moving on with life after diagnosis and treatment, and have poorer quality of life. It is a prevalent and 
persistent issue for cancer survivors, with significant costs for the individual, family and society. Those who 
are younger have greater symptom burden and greater psychological distress are likely to have higher fear of 
cancer recurrence. Few intervention studies have been reported in the literature to date to guide health service 
provision. However, several studies are currently underway in Australia to develop empirically tested theory-driven 
interventions.
Improved medical treatments for cancer have led to 
higher survival rates; the five-year relative survival in 
Australia is currently 66% for all cancers combined.1 In 
response, research has increasingly focused on longer-
term survivorship issues. One of the most prevalent 
and severe unmet supportive care needs in cancer 
survivors, that does not appear to diminish with time since 
diagnosis, is for help with fear of cancer recurrence.2,3 This 
review aims to present current research on this, together 
with interventions currently under investigation from an 
Australian perspective.
Conceptualisation and measurement of fear 
of cancer recurrence
Conceptualisation of fear of cancer recurrence is still 
evolving, with no widely-accepted understanding of 
its nature or clinical significance. However, Vickberg’s 
definition of fear of cancer recurrence: “The fear or 
worry that cancer could return or progress in the same 
place or another part of the body,” has frequently 
been employed.3 Fear of cancer recurrence has 
been characterised as multidimensional, comprising 
emotional, cognitive and behavioural reactions.4 
Numerous measures have been published that attempt 
to evaluate the nature and severity of fear of cancer 
recurrence, but each uses a slightly different approach, 
employing different definitions and emphasising different 
aspects of fear of recurrence. Consequently, the setting 
and purpose of evaluating fear or recurrence should be 
considered when selecting a measure.5 
The clinical significance of fear of cancer recurrence is 
unclear. Despite an apparent association between fear 
of recurrence and quality of life (QOL), little work has 
investigated the level or severity of fear of recurrence at 
which it begins to impact daily life. To date, one study 
has attempted to establish a clinical cut-off score for fear 
of cancer recurrence (on the Fear of Cancer Recurrence 
Inventory Severity Subscale).6,7 However, the purpose-
designed diagnostic interview used in that study has not 
yet been validated, so the proposed cut-off of 13 can 
only be considered preliminary. There is some evidence 
suggesting this cut-off has strong sensitivity but poor 
discrimination, and may falsely identify many people with 
clinical levels of fear of cancer recurrence.8 In the absence 
of established clinical cut-offs, researchers have employed 
more descriptive approaches. For example, Lebel et al 
considered women with breast or ovarian cancer had 
moderate to high levels of fear of recurrence when they 
endorsed more than 50% of the 22 items on the Fear of 
cancer recurrence questionnaire with a 4 or 5 (item range 
1-5), and scored in the clinical range which involves total 
score ≥26, range 0-75 on the validated Impact of Event 
Scale.9,10,11
Prevalence of fear of cancer recurrence
Some degree of fear of cancer recurrence is reported 
by almost all cancer survivors and their caregivers.12,13 
For example, of 1442 Australian adult cancer survivors 
diagnosed with one of the eight most common cancers, 
46% worried about their cancer returning or getting worse 
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at 12 months post-diagnosis.14 A recent systematic review 
found that across different cancer sites and assessment 
strategies: 39-97% of cancer survivors reported some 
degree of fear of recurrence (on average 73%); 22-87% 
reported moderate to high fear of recurrence (on average 
49%); and 0-15% reported high fear of recurrence (on 
average 7%).15 Some studies have reported even higher 
levels of fear of recurrence among caregivers than 
patients.12 The wide range in prevalence estimates appears 
due to several factors, including different definitions such 
as fear of progression versus fear of recurrence, together 
with measures and sample characteristics.16
Fear of cancer recurrence does not always decrease with 
time, even when the risk of recurrence is low.15,16 The 
above-mentioned systematic review identified 21 cross-
sectional studies exploring associations between time 
since diagnosis and fear of cancer recurrence severity, 
with only one study reporting a significant association,15,17 
reinforcing the stability of fear of recurrence over time.18 In 
their longitudinal study, Ghazali et al reported that among 
head and neck cancer survivors: approximately 50% did 
not experience significant levels of fear of recurrence; 
approximately 20% experienced significant levels of 
fear of recurrence intermittently; and approximately 
30% experienced stable and significant levels of fear or 
recurrence over time.19 Furthermore, for this last group, 
fear of recurrence scores did not fluctuate, remaining high 
over time.
Predictors of fear of cancer recurrence
Younger age is consistently associated with higher fear 
of cancer recurrence.3,13,20 There is inconsistent evidence 
that females, minority groups, and those with lower 
education, lower income, or in employment, experience 
higher fear of recurrence.15 Fulfilling a caregiving role, 
such as being a young mother, has been associated 
with higher fear of recurrence,21,22 although another study 
found no association between having children, attitudes 
to future pregnancy, and fear of recurrence in young 
breast cancer survivors.23 Thus the contribution of many 
socio-demographic variables to fear of cancer recurrence 
remains uncertain. 
Counter-intuitively, fear of cancer recurrence is not clearly 
linked to prognostic indicators such as stage of disease 
and treatment received.16,24 For example, in one review, 
prognostic indicators including TNM stage, prostate-
specific antigen level, Gleason score and presence of 
positive margin, were positively associated with fear of 
cancer recurrence in 11 studies, but 16 studies reported 
no association.15 Similarly, having had a recurrence or 
metastatic diagnosis was significantly associated with 
fear of recurrence in five studies, but unrelated in four. 
However, high subjective risk, illness perceptions and 
intrusive thoughts have consistently been associated 
with higher fear of recurrence, while optimism has been 
associated with lower fear of recurrence.15,16,25 This 
suggests that assessment and review of unrealistically 
high subjective risk, may be a strategy for combating fear 
of cancer recurrence.26 
There is strong evidence for a relationship between fear of 
cancer recurrence and symptom experience, particularly 
global symptom burden, pain, fatigue and body image 
concerns.15,16,24 These symptoms may remind survivors 
of their cancer diagnosis,27 and be interpreted as possible 
signs of recurrence, thereby increasing fear of cancer 
recurrence. These results suggest that education about 
the meaning of symptoms and those likely to be related 
to recurrence may be helpful. 
With regards to psychological predictors of fear of 
cancer recurrence, general distress, depression, anxiety 
and avoidance have been associated with higher fear 
of recurrence.15,16,25 Some studies have also reported 
an association between fear of cancer recurrence and 
diagnosed anxiety or psychiatric conditions such as 
post-traumatic stress disorder, global anxiety disorder, 
hypochondriasis and obsessive compulsive disorder,23,28,29 
although most cancer survivors do not appear to 
suffer such co-morbidities.23 The relationship between 
psychological factors and fear of cancer recurrence is 
most likely bi-directional.15 
Consequences of fear of cancer recurrence
Adjustment to the possibility of cancer recurrence is 
sometimes reported as more problematic than adjustment 
to the initial diagnosis.30 High fear of recurrence levels 
have been shown to have a negative impact on QOL, 
psychological adjustment, emotional distress and anxiety, 
ability to establish future goals and plans, and carer 
QOL.15,16,25,31 However, Simard et al argue that the large 
number of concepts explored means the evidence base 
for any one psychological impact is weak.15 Furthermore, 
Lebel et al showed that change in fear of cancer 
recurrence did not lead to changes in distress and 
intrusions/avoidance over time.32
Fear of cancer recurrence has been associated with higher 
use of medical services, including complementary and 
alternative medicines, and increased medical costs.13,33 
For example, in Australian early-stage breast cancer 
survivors approximately four years post-diagnosis, those 
with higher fear of cancer recurrence were more likely 
to have unscheduled GP visits and use complementary 
therapies.13 These women were also more likely to engage 
in breast self-examination, but avoid formal screening 
measures such as mammograms and ultrasounds, 
potentially compromising health outcomes.13 Thus the 
impact of high fear of recurrence is wide-ranging, with 
potential costs to the individual, the family and wider 
society.
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Unmet need for help with managing fear of 
cancer recurrence
Despite the high prevalence and potential cost of fear 
of cancer recurrence, survivors report high levels of 
unmet need for help managing this fear, suggesting 
many cancer services are not currently providing 
adequate care in this area. A multi-centre Australian 
study (n=388) found that fear of cancer recurrence 
was survivors’ greatest area of unmet need, with 26% 
reporting moderate to high unmet need for help with 
this fear.34 The need for effective interventions for fear 
of recurrence has been recognised by oncology health 
professionals. In a survey of 141 Australian medical 
and radiation oncologists, surgeons, nurses, palliative 
care specialists, psychiatrists, psychologists and social 
workers, 33% reported spending more than 25% of 
follow-up consultation time discussing fear of cancer 
recurrence, 46% found dealing with this challenging and 
almost all were interested in further training for managing 
patients with this fear.35 These results emphasise the 
need for developing effective, theory and evidence-
based treatments for fear of cancer recurrence.
Theoretical perspectives on fear of cancer 
recurrence
Several theoretical models have been previously used 
to explain fear of cancer recurrence, though none is 
universally accepted. These are presented below.
Theory of uncertainty in illness
Although uncertainty is not the same as fear of cancer 
recurrence, aspects of Mishel’s theory of uncertainty in 
illness may be relevant to understanding this fear.36,37 
According to this theory, uncertainty is the inability to 
determine the meaning of illness-related events.36 It is 
generated when there is inconsistency, randomness, 
complexity, unpredictability and little information about 
the illness, its treatment, and related events including 
symptoms.36 Integrating uncertainty into one’s life and 
directing it in a desired direction such as reduced 
uncertainty is an essential task in adaption.37 Uncertainty 
about the possibility of cancer recurrence is similarly 
triggered by intrusive, unpredictable and random 
events.38 The difficulty with this causal explanation of fear 
of cancer recurrence is that some degree of uncertainty 
about recurrence likely exists for all cancer survivors, yet 
not all cancer survivors develop clinically significant levels 
of fear of recurrence. 
Self-regulation of illness/common sense model
The self-regulation of illness or common sense model 
proposes that when individuals are confronted with 
a health threat, an illness representation is activated 
consisting of cognitive factors, meaning perceived 
personal risk of recurrence and emotional considerations 
including worry about the cancer returning, anxiety 
about cancer itself, and regret about treatment 
decisions and these motivational processing systems, 
act together to guide coping behaviours.4,39,40 Lee-
Jones et al hypothesised that survivors who viewed 
their cancer as chronic, with negative and uncontrollable 
consequences, were likely to engage in more emotional 
processing of health threats and have higher fear 
of cancer recurrence.4 There is some evidence for 
the common sense model in dealing with fear of 
recurrence; individuals who believe they are vulnerable 
to cancer are more emotionally aroused by somatic 
stimuli and display higher levels of fear of recurrence, 
while adaptive coping strategies are associated with 
lower fear of recurrence.4,41-43 However, this model 
does not address how survivors come to have negative 
cognitive and emotional responses to cancer. 
Self-regulatory executive function model of 
anxiety disorders
The self-regulatory executive function model addresses 
maintaining factors associated with anxiety disorders 
and has been used to effectively treat health anxiety.44,45-47 
The model proposes the cognitive attentional syndrome 
which consists of: self-focused attention, worry and 
rumination; attentional bias towards threat-related 
information; and maladaptive coping behaviours 
including suppression, avoidance and minimisation. 
Cognitive attentional syndrome impairs flexible self-
control and prevents corrective learning experiences, 
leading to increased and persistent distressing 
emotions. The self-regulatory executive function model 
argues that beliefs about one’s thoughts underlie 
activation of cognitive attentional syndrome.44 That is, 
those who believe worry is important and may impact 
the outcome (e.g. “If I worry I will be prepared”) are 
more likely to engage in cognitive attentional syndrome, 
in turn intensifying fears and worries about cancer 
returning. Research has shown that anxious cancer 
patients display an attentional bias towards threatening 
stimuli,48-50 and fear of recurrence level appears to 
be associated with metacognitions and beliefs about 
cancer vulnerability.4,41-43 The self-regulatory executive 
function model appears particularly applicable to fear of 
recurrence because the belief that cancer might recur 
is not entirely irrational, and hence a focus on cognitive 
processes rather than content could be advantageous, 
and it explains why elevated emotional responses after 
cancer diagnosis are maintained.40 
Relational frame theory and acceptance and 
commitment therapy 
Acceptance and commitment therapy,51 based on 
relational frame theory, focuses on increasing cognitive 
flexibility and emphasises accepting feelings, thoughts 
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and sensations when attempts to control them are 
counterproductive and prevent the individual acting in 
line with desired goals and values.51,52 Acceptance and 
commitment therapy can address the existential issues 
that arise when cancer is diagnosed, as it aims to help 
clients develop more clarity about what is important to 
them and to establish behavioural goals in accordance with 
those values.51 Acceptance and commitment therapy has 
recently been applied in the cancer context with promising 
results.53-55 Also, while it is yet to be empirically evaluated 
in randomised control trials, Australian psychosocial-
oncology health professionals report acceptance and 
commitment therapy offers clinically useful strategies for 
treating fear of cancer recurrence.35
Intervention studies
The AFTER intervention (Adjustment to Fear, Threat 
or Expectation of Recurrence) was one of the first 
psychological interventions specifically designed to 
address fear of cancer recurrence in head and neck 
cancer patients.56,57 This intervention, based on the 
common sense model, consisted of six face-to-face 
individual sessions with a specialist nurse and encouraged 
participants to discuss the likelihood of recurrence, 
express cancer recurrence-related fears, their triggers and 
consequences. The manualised sessions also covered 
excessive checking behaviours and illness beliefs and 
representations.56,57 Two assessments were carried out 
before the intervention, at three and seven months 
post-treatment completion, and two after, at 11 and 
15 months post-treatment completion. The intervention 
group maintained general anxiety levels before and after 
the intervention, while the control group had increased 
anxiety. There was a statistically significant improvement 
in fear of cancer recurrence for the intervention versus 
control participants immediately post-intervention, that 
was not maintained at 15 months. A significant limitation of 
the trial was its lack of statistical power. Also, participants 
were not screened for high levels of fear of cancer 
recurrence prior to study entry, and together with using 
a three-item fear of cancer recurrence measure, this may 
have contributed to the mild effects found.
Lebel et al developed a manualised six week cognitive 
existential group intervention targeting fear of cancer 
recurrence based on the common sense model,9 Mishel’s 
uncertainty in illness theory, cognitive models of worry and 
components of a cognitive-existential group intervention.58 
Stage I-III breast and ovarian cancer patients were eligible 
for this single-arm pilot if they reported clinically significant 
fear of cancer recurrence levels (discussed above) and 
had completed primary treatment. Immediately post-
intervention, women experienced significantly lower fear of 
cancer recurrence, plus significantly lower cancer-specific 
distress, uncertainty and negative QOL. Changes were 
maintained at three-month follow-up. These preliminary 
positive results are tempered by 12 of 56 participants 
(21%) dropping out over the course of the intervention.
Several studies investigated interventions targeting 
concepts similar to fear of cancer recurrence. Herschbach 
et al compared cognitive behaviour group therapy or 
supportive-experiential group therapy with usual care 
over 12 months on fear of progression,59,60 with both 
intervention groups showing significant reductions in fear 
of progression over time compared to controls. Heinrichs 
et al similarly showed that a couple-skills intervention 
reduced fear of progression compared to a control cancer 
education program in breast and gynaecological cancer 
patients and their carers.61 However, these benefits were 
not maintained at follow-up, 16 months post-diagnosis. 
A third study reported that a nurse-led telephone 
intervention for uncertainty management in long-term 
breast cancer survivors increased cognitive reframing and 
cancer knowledge compared to usual care controls.38 
Though they did not specifically target fear of cancer 
recurrence, in a single arm pilot study Chambers et 
al found a non-significant trend for decreased fear of 
recurrence in Australian men diagnosed with advanced 
prostate cancer, who participated in an eight-week 
mindfulness-based program three months post-treatment 
completion.62 Lengacher et al reported on a six-eight 
session Mindfulness-Based Stress Reduction group 
program designed to improve psychological status 
generally.63-65 Significant improvements were seen in fear 
of recurrence, as well as depression and anxiety, though 
no long-term data has been published.63 Thus further 
research evaluating fear of cancer recurrence specific 
interventions is required.
There are two interventions currently underway in Australia 
which specifically target fear of cancer recurrence.* 
The first is a multi-centre randomised trial comparing a 
novel psychological intervention called 'Conquer Fear' to 
relaxation training for cancer patients.40 Both interventions 
are manualised and delivered in five sessions over 5-10 
weeks by trained psychologists and psychiatrists. Eligible 
participants are breast, colorectal or melanoma cancer 
survivors who have completed hospital-based treatment 
between two months and five years prior, and report a 
score in the clinical range on the Fear of Cancer Recurrence 
Inventory Severity Subscale. Conquer Fear incorporates 
aspects of the self-regulatory executive function model 
and relational frame theory, together with the common 
*A review of the Australian and New Zealand Clinical Trials Registry on 24th July 2014, found only two studies registered with fear of cancer 
recurrence as the primary outcome measure. The authors acknowledge other Australian groups may be undertaking research on novel 
interventions or therapeutic approaches for managing fear of cancer recurrence, but at the time of writing this article they were not registered 
with Australian and New Zealand Clinical Trials Registry
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sense model, to provide a novel metacognitive account of 
fear of recurrence. The sessions cover attention training, 
detached mindfulness, meta-cognitive therapy, values 
clarification and psycho-education to help cancer survivors 
change how they regulate and respond to thoughts about 
cancer recurrence. The relaxation training arm focuses on 
both internal and external stressors associated with fear of 
recurrence, and teaches progressive and passive muscle 
relaxation, meditative relaxation, visualisation and ‘quick 
relaxation’ techniques. The primary outcome measure 
is fear of cancer recurrence as measured by the Fear 
of Cancer Recurrence Inventory, and participants are 
followed up for six months after intervention completion. 
This trial is currently recruiting and due for completion 
in 2016. The second trial in progress is a randomised 
trial comparing a novel psycho-educational intervention 
for high-risk melanoma cancer patients to usual care.66 
The psycho-educational intervention comprises a 
tailored, psycho-educational booklet and three individual, 
telephone-based counselling sessions delivered by 
a clinical psychologist focused around their high-risk 
melanoma clinic appointments. The primary outcome 
is fear of cancer recurrence as measured by the fear, 
assessed two-three weeks after their first high risk clinic 
appointment and again at five and 11 months afterwards.
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